158 related articles for article (PubMed ID: 32458584)
1. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation.
Wu Y; Ni J; Chang X; Zhang X; Zhang L
Thorac Cancer; 2020 Jul; 11(7):2051-2055. PubMed ID: 32458584
[TBL] [Abstract][Full Text] [Related]
2. Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Ni J; Si XY; Zhang L
Thorac Cancer; 2021 Apr; 12(8):1244-1247. PubMed ID: 33655632
[TBL] [Abstract][Full Text] [Related]
3. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
4. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.
Luo Y; Yao B; Huang P; Zhao Y; Chen J
Ann Palliat Med; 2021 Dec; 10(12):12906-12910. PubMed ID: 35016465
[TBL] [Abstract][Full Text] [Related]
6. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
[TBL] [Abstract][Full Text] [Related]
7. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
[TBL] [Abstract][Full Text] [Related]
10. Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report.
Zhao H; Yang H; Yu X; Feng H; Yang F
Anticancer Drugs; 2022 Jun; 33(5):509-512. PubMed ID: 35324516
[TBL] [Abstract][Full Text] [Related]
11. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
13. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
[TBL] [Abstract][Full Text] [Related]
14. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.
Dai J; Chen Y; Tang C; Wei X; Gong Y; Wei J; Gu D; Chen J
Medicine (Baltimore); 2020 Jun; 99(25):e20809. PubMed ID: 32569228
[TBL] [Abstract][Full Text] [Related]
15. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer.
de Oliveira Cavagna R; Zaniolo BG; de Paula FE; Berardinelli GN; Santana I; da Silva ECA; Dias JM; Jacinto AA; da Nóbrega Oliveira REN; de Marchi P; Leal LF; Reis RM
Thorac Cancer; 2022 Dec; 13(23):3402-3407. PubMed ID: 36251951
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
[TBL] [Abstract][Full Text] [Related]
18.
Li H; Li X; Lan S; Zuo X; Du T; Liu Y; Zhang C; Zhu J; Cheng Y
Tumori; 2023 Jun; 109(3):276-281. PubMed ID: 35723064
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib in
Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
[TBL] [Abstract][Full Text] [Related]
20. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
